This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ChemoCentryx Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

n/a

Dividendenausschüttung

-0.2%

Rückkaufsrendite

Gesamte Aktionärsrendite	-0.2%
Zukünftige Dividendenrendite	n/a
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

ChemoCentryx shareholders approve $4.7B merger with Amgen

Oct 18

ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M

Aug 09

Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week

Jan 21

Checking In On ChemoCentryx

Dec 15

Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?

Oct 09

ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way

Sep 29

ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends

Aug 24

Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook

Aug 11

ChemoCentryx: CRL Less Likely

Jul 25

ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price

Jul 11

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jun 15

ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress

Jun 08

ChemoCentryx: CRL Likely

May 09

ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action

May 07

Chemocentryx shares plunge 47% as FDA report identifies concerns with vasculitis candidate

May 04

When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?

Mar 03

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 04

ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price

Jan 14

Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?

Dec 31

Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)

Dec 23

ChemoCentryx's avacopan flunks mid-stage study in rare kidney disease study

Dec 21

Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?

Dec 13

Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?

Nov 22

ChemoCentryx, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 10

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von CCXI in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von CCXI gestiegen sind.

Dividendenrendite im Vergleich zum Markt

ChemoCentryx Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von CCXI im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (CCXI)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.4%
Branchendurchschnitt (Biotechs)	2.4%
Analystenprognose (CCXI) (bis zu 3 Jahre)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von CCXI im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von CCXI im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von CCXI, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da CCXI keine Ausschüttungen gemeldet hat.

Entdecken Sie dividendenstarke Unternehmen

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2022/10/23 04:01
Aktienkurs zum Tagesende	2022/10/19 00:00
Gewinne	2022/06/30
Jährliche Einnahmen	2021/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

^* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .

Analysten-Quellen

ChemoCentryx, Inc. wird von 15 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Madhu Kumar	B. Riley Securities, Inc.
Harshita Polishetty	B. Riley Securities, Inc.
Dae Gon Ha	BTIG

This company listing is no longer active

ChemoCentryx Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of ChemoCentryx, Inc. (NasdaqGS:CCXI) from a group of shareholders.

Chemocentryx, Inc. Announces Executive Changes

ChemoCentryx shareholders approve $4.7B merger with Amgen

Executive VP exercised options and sold US$798k worth of stock

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M

Founder notifies of intention to sell stock

Price target decreased to US$54.29

Amgen Inc. (NasdaqGS:AMGN) entered into a definitive agreement to acquire ChemoCentryx, Inc. (NasdaqGS:CCXI) for $3.7 billion.

ChemoCentryx, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Chemocentryx, Inc. Announces Appointment of Jennifer L. Herron to Board as Independent Director

ChemoCentryx: Revisiting The Investment Case

Independent Director notifies of intention to sell stock

ChemoCentryx, Inc. Appoints Yi Ching Yau as Senior Vice President, Finance and Principal Accounting Officer

Chemocentryx Inc. Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered Pd-L1 Inhibitor, Ccx559, At the 2022 American Society of Clinical Oncology (Asco) Annual Meeting

ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

ChemoCentryx Announces Changes to its Board of Directors

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Independent Director exercised options to buy US$212k worth of stock.

Insufficient new directors

ChemoCentryx, Inc. Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, Ccx559, At American Association for Cancer Research (Aacr) Annual Meeting 2022

ChemoCentryx, Inc., Annual General Meeting, May 26, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

ChemoCentryx: Good Post-Approval Performance, But Needs More Time

Consensus revenue estimates fall by 13%

ChemoCentryx, Inc. to Report Q4, 2021 Results on Mar 01, 2022

ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?

Independent Director exercised options to buy US$905k worth of stock.

Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week

ChemoCentryx, Inc Announces EU Approval of Tavneos® (Avacopan) for the Treatment of ANCA-Associated Vasculitis

Consensus revenue estimates fall by 13%

Founder exercised options and sold US$1.7m worth of stock

Forecast to breakeven in 2024

Independent Director exercised options and sold US$817k worth of stock

Checking In On ChemoCentryx

Founder exercised options to buy US$1.6m worth of stock.

Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.35 loss in 3Q 2020)

Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?

Price target increased to US$68.43

ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way

ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis

ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.32 profit in 2Q 2020)

Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook

Consensus forecasts updated

ChemoCentryx: CRL Less Likely

ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price

Rosen Law Firm Encourages ChemoCentryx, Inc. Investors with Losses to Secure Counsel Before Important July 6, 2021 Deadline in Securities Class Action

ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress

Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed against ChemoCentryx, Inc

Executive VP & COO recently bought US$120k worth of stock

Consensus revenue estimates fall to US$38.2m

ChemoCentryx: CRL Likely

ChemoCentryx Announces Results of U.S. Food and Drug Administration Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis

Price target decreased to US$78.75

ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against ChemoCentryx, Inc

Chemocentryx shares plunge 47% as FDA report identifies concerns with vasculitis candidate

First quarter 2021 earnings released: US$0.43 loss per share (vs US$0.35 loss in 1Q 2020)

Director recently sold US$1.8m worth of stock

ChemoCentryx, Inc Appoint Susan M. Kanaya to the Board of Directors

Analysts update estimates

Senior VP exercised options and sold US$1.9m worth of stock

When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?

ChemoCentryx, Inc. Appoints Tausif Butt as Executive Vice President and Chief Operating Officer

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: US$0.84 loss per share (vs US$0.97 loss in FY 2019)

New 90-day high: US$68.40

Chemocentryx Appoints Tausif (‘Tosh’) Butt as Executive Vice President and Chief Operating Officer

ChemoCentryx, Inc. to Report Q4, 2020 Results on Mar 01, 2021

ChemoCentryx Announces Publication in the New England Journal of Medicine of Results of the Pivotal Phase III Advocate Trial of Avacopan for the Treatment of Anca-Associated Vasculitis